3,4-二氯喹啉-2-胺 | 73987-35-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 3,4-二氯喹啉-2-胺
• 英文名称: 2-Amino-3,4-dichloroquinoline
• 英文别名: 3,4-dichloroquinolin-2-amine
• CAS: 73987-35-6
• 化学式: C₉H₆Cl₂N₂
• 分子量: 213.06
• InChiKey: TZFJDFLGRAVDCT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  38.9
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• SUBSTITUTED 2,4 DIAMINO-QUINOLINE AS NEW MEDICAMENT FOR FIBROSIS, AUTOPHAGY AND CATHEPSINS B (CTSB), L (CTSL) AND D (CTSD) RELATED DISEASES
  申请人：Genoscience Pharma SAS

  公开号：EP3620164A1

  公开（公告）日：2020-03-11

  The present invention relates to novel 2-primary amino-4-secondary amino-quinoline derivatives, their manufacture, pharmaceutical compositions comprising them and their use as medicaments. The active compounds of the present invention can be useful as a medicament in the treatment and/or the decreasing and/or the prevention of fibrosis and/or fibrosis related diseases, or for use as a medicament in the treatment and/or the decreasing and/or the prevention of the autophagy and/or autophagy related diseases and for the inhibition of the autophagy flux, or for use in the inhibition of cathepsins B (CTSB), L (CTSL) and/or D (CTSD) and/or cathepsins B (CTSB), L (CTSL) and/or D (CTSD) related diseases; with the proviso that said compounds are not to be used for the treatment of any forms of cancers.

  本发明涉及新型2-初级氨基-4-次级氨基喹啉衍生物，其制备方法，包含它们的药物组合物以及它们作为药物的用途。本发明的活性化合物可用作药物治疗和/或减少和/或预防纤维化和/或与纤维化相关疾病，或用作药物治疗和/或减少和/或预防自噬和/或与自噬相关疾病以及抑制自噬通量，或用于抑制蛋白酶B（CTSB）、L（CTSL）和/或D（CTSD）和/或与蛋白酶B（CTSB）、L（CTSL）和/或D（CTSD）相关疾病；但所述化合物不得用于治疗任何形式的癌症。
• Substituted 2,4 diamino-quinoline as new medicament for fibrosis, autophagy and cathepsins B (CTSB), L (CTSL) and D (CTSD) related diseases
  申请人：Genoscience Pharma

  公开号：US11261189B2

  公开（公告）日：2022-03-01

  2-primary amino-4-secondary amino-quinoline derivatives, their manufacture, pharmaceutical compositions comprising them and their use as medicaments are disclosed. The compounds are useful as a medicament in treating and/or decreasing the severity and/or progression and/or preventing fibrosis and/or related diseases, or for use as a medicament in treating, decreasing the severity and/or progression of and/or preventing autophagy and/or related diseases, for inhibiting autophagy flux, and for inhibiting cathepsins B (CTSB), L (CTSL) and/or D (CTSD) and/or related diseases.

  本发明公开了2-原氨基-4-仲氨基-喹啉衍生物、其制造方法、包含它们的药物组合物及其作为药物的用途。这些化合物可用作治疗和/或降低纤维化和/或相关疾病的严重程度和/或其进展和/或预防纤维化和/或相关疾病的药物，或用作治疗、降低自噬和/或相关疾病的严重程度和/或其进展和/或预防自噬和/或相关疾病的药物，用于抑制自噬通量，以及抑制酪蛋白B（CTSB）、L（CTSL）和/或D（CTSD）和/或相关疾病。
• TREATMENTS FOR NEUROPATHY
  申请人：Children's Medical Center Corporation

  公开号：EP2240177A2

  公开（公告）日：2010-10-20
• Treatments for Neuropathy
  申请人：Corfas Gabriel

  公开号：US20110086878A1

  公开（公告）日：2011-04-14

  Small fiber neuropathy is treated or prevented by topically administering to a subject in need thereof topically active quinoline compounds or pharmaceutically acceptable salts thereof under conditions effective to treat or prevent neuropathy in the subject. Glial cell-derived neurotrophic factor (GDNF) receptors are modulated with the subject active quinoline compounds, which may be formulated in topical lotions.
• COMPOSITIONS AND METHODS FOR TREATING NEUROPATHY
  申请人：CHILDEREN'S MEDICAL CENTER CORPORATION

  公开号：US20160045487A1

  公开（公告）日：2016-02-18

  The invention features XIB4035 for the treatment of large fiber neuropathy, and combinations of XIB4035 and GDNF for the treatment of both large and small fiber neuropathies.